---
document_datetime: 2025-12-02 06:58:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-teva.html
document_name: temozolomide-teva.html
version: success
processing_time: 0.1266138
conversion_datetime: 2025-12-29 20:04:47.841132
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Temozolomide Teva

[RSS](/en/individual-human-medicine.xml/65420)

##### Authorised

This medicine is authorised for use in the European Union

temozolomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Temozolomide Teva](#more-information-on-temozolomide-teva-964)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Temozolomide Teva?

Temozolomide Teva is a medicine that contains the active substance temozolomide. It is available as capsules (5, 20, 100, 140, 180 and 250 mg).

Temozolomide Teva is a 'generic medicine'. This means that Temozolomide Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Temodal.

## What is Temozolomide Teva used for?

Temozolomide Teva is a cancer medicine. It is used to treat malignant glioma (brain tumours) in the following groups of patients:

- adults with newly diagnosed glioblastoma multiforme (an aggressive type of malignant glioma). Temozolomide Teva is used first with radiotherapy and then on its own;
- adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment. Temozolomide Teva is used on its own in these patients.

The medicine can only be obtained with a prescription.

## How is Temozolomide Teva used?

Treatment with Temozolomide Teva should be prescribed by a doctor with experience in the treatment of brain tumours.

The dose of Temozolomide Teva depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day. The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Teva is being used alone or with other treatments, and how the patient responds to treatment. Temozolomide Teva should be taken without food.

Patients may also need to take medicines to prevent vomiting before taking Temozolomide Teva. Temozolomide Teva should be used with caution in patients with severe liver problems or with kidney problems.

For full details, see the summary of product characteristics (also part of the EPAR).

## How does Temozolomide Teva work?

The active substance in Temozolomide Teva, temozolomide, belongs to a group of cancer medicines called alkylating agents. In the body, temozolomide is converted to another compound called MTIC. MTIC binds to the DNA of cells while they are reproducing, which stops cell division. As a result, the cancer cells cannot divide, slowing down the growth of tumours.

## How has Temozolomide Teva been studied?

Because Temozolomide Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Temozolomide Teva?

Because Temozolomide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.

## Why has Temozolomide Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Temozolomide Teva has been shown to have comparable quality and to be bioequivalent to Temodal. Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk. The Committee recommended that Temozolomide Teva be given marketing authorisation.

## Other information about Temozolomide Teva

The European Commission granted a marketing authorisation valid throughout the EU for Temozolomide Teva on 28 January 2010.

For more information about treatment with Temozolomide Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Temozolomide Teva : EPAR - Summary for the public

English (EN) (78.15 KB - PDF)

**First published:** 11/02/2010

**Last updated:** 18/09/2014

[View](/en/documents/overview/temozolomide-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-84)

български (BG) (105.73 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/bg/documents/overview/temozolomide-teva-epar-summary-public_bg.pdf)

español (ES) (79.34 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/es/documents/overview/temozolomide-teva-epar-summary-public_es.pdf)

čeština (CS) (104.19 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/cs/documents/overview/temozolomide-teva-epar-summary-public_cs.pdf)

dansk (DA) (77.63 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/da/documents/overview/temozolomide-teva-epar-summary-public_da.pdf)

Deutsch (DE) (79.22 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/de/documents/overview/temozolomide-teva-epar-summary-public_de.pdf)

eesti keel (ET) (77.42 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/et/documents/overview/temozolomide-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (103.64 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/el/documents/overview/temozolomide-teva-epar-summary-public_el.pdf)

français (FR) (102.5 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/fr/documents/overview/temozolomide-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (93.97 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/hr/documents/overview/temozolomide-teva-epar-summary-public_hr.pdf)

italiano (IT) (77.98 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/it/documents/overview/temozolomide-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.87 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/lv/documents/overview/temozolomide-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (122.29 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/lt/documents/overview/temozolomide-teva-epar-summary-public_lt.pdf)

magyar (HU) (99.75 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/hu/documents/overview/temozolomide-teva-epar-summary-public_hu.pdf)

Malti (MT) (105.02 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/mt/documents/overview/temozolomide-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (80.04 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/nl/documents/overview/temozolomide-teva-epar-summary-public_nl.pdf)

polski (PL) (103.57 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/pl/documents/overview/temozolomide-teva-epar-summary-public_pl.pdf)

português (PT) (80.37 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/pt/documents/overview/temozolomide-teva-epar-summary-public_pt.pdf)

română (RO) (99.99 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/ro/documents/overview/temozolomide-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (101.23 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/sk/documents/overview/temozolomide-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (93.41 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/sl/documents/overview/temozolomide-teva-epar-summary-public_sl.pdf)

Suomi (FI) (78.68 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/fi/documents/overview/temozolomide-teva-epar-summary-public_fi.pdf)

svenska (SV) (77.45 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

18/09/2014

[View](/sv/documents/overview/temozolomide-teva-epar-summary-public_sv.pdf)

## Product information

Temozolomide Teva : EPAR - Product Information

English (EN) (547.83 KB - PDF)

**First published:** 11/02/2010

**Last updated:** 16/05/2024

[View](/en/documents/product-information/temozolomide-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-375)

български (BG) (685.27 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/bg/documents/product-information/temozolomide-teva-epar-product-information_bg.pdf)

español (ES) (611.66 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/es/documents/product-information/temozolomide-teva-epar-product-information_es.pdf)

čeština (CS) (635.13 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/cs/documents/product-information/temozolomide-teva-epar-product-information_cs.pdf)

dansk (DA) (877.75 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/da/documents/product-information/temozolomide-teva-epar-product-information_da.pdf)

Deutsch (DE) (617.68 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/de/documents/product-information/temozolomide-teva-epar-product-information_de.pdf)

eesti keel (ET) (534.02 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/et/documents/product-information/temozolomide-teva-epar-product-information_et.pdf)

ελληνικά (EL) (707.98 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/el/documents/product-information/temozolomide-teva-epar-product-information_el.pdf)

français (FR) (619.06 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/fr/documents/product-information/temozolomide-teva-epar-product-information_fr.pdf)

hrvatski (HR) (629.5 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/hr/documents/product-information/temozolomide-teva-epar-product-information_hr.pdf)

íslenska (IS) (622.47 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/is/documents/product-information/temozolomide-teva-epar-product-information_is.pdf)

italiano (IT) (617.33 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/it/documents/product-information/temozolomide-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (644.4 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/lv/documents/product-information/temozolomide-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (633.42 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/lt/documents/product-information/temozolomide-teva-epar-product-information_lt.pdf)

magyar (HU) (641.25 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/hu/documents/product-information/temozolomide-teva-epar-product-information_hu.pdf)

Malti (MT) (688.23 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/mt/documents/product-information/temozolomide-teva-epar-product-information_mt.pdf)

Nederlands (NL) (582.97 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/nl/documents/product-information/temozolomide-teva-epar-product-information_nl.pdf)

norsk (NO) (621.52 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/no/documents/product-information/temozolomide-teva-epar-product-information_no.pdf)

polski (PL) (695.63 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/pl/documents/product-information/temozolomide-teva-epar-product-information_pl.pdf)

português (PT) (553.62 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/pt/documents/product-information/temozolomide-teva-epar-product-information_pt.pdf)

română (RO) (638.33 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/ro/documents/product-information/temozolomide-teva-epar-product-information_ro.pdf)

slovenčina (SK) (647.34 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/sk/documents/product-information/temozolomide-teva-epar-product-information_sk.pdf)

slovenščina (SL) (616.71 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/sl/documents/product-information/temozolomide-teva-epar-product-information_sl.pdf)

Suomi (FI) (637.66 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/fi/documents/product-information/temozolomide-teva-epar-product-information_fi.pdf)

svenska (SV) (599.06 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

16/05/2024

[View](/sv/documents/product-information/temozolomide-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000170853 07/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Temozolomide Teva : EPAR - All Authorised presentations

English (EN) (30.63 KB - PDF)

**First published:** 11/02/2010

**Last updated:** 11/02/2010

[View](/en/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-499)

български (BG) (98.69 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/bg/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.58 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/es/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (93.14 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/cs/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.56 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/da/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (31.14 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/de/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (31.7 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/et/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (92.74 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/el/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (12.56 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/fr/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (12.09 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/it/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (95.02 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/lv/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (95.68 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/lt/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (42.36 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/hu/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (96.91 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/mt/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (31.03 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/nl/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_nl.pdf)

polski (PL) (97.94 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/pl/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (31.18 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/pt/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (93.61 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/ro/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (94.77 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/sk/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.49 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/sl/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.01 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/fi/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (31.95 KB - PDF)

**First published:**

11/02/2010

**Last updated:**

11/02/2010

[View](/sv/documents/all-authorised-presentations/temozolomide-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Temozolomide Teva Active substance temozolomide International non-proprietary name (INN) or common name temozolomide Therapeutic area (MeSH) Glioma Anatomical therapeutic chemical (ATC) code L01AX03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.

For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

## Authorisation details

EMA product number EMEA/H/C/001126

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Teva B.V.

Marketing authorisation issued 28/01/2010 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Temozolomide Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.04 KB - PDF)

**First published:** 16/05/2024

[View](/en/documents/procedural-steps-after/temozolomide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Temozolomide Teva : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (198.9 KB - PDF)

**First published:** 17/05/2010

**Last updated:** 18/02/2022

[View](/en/documents/procedural-steps-after/temozolomide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Temozolomide Teva : EPAR - Public assessment report

English (EN) (219.96 KB - PDF)

**First published:** 11/02/2010

**Last updated:** 11/02/2010

[View](/en/documents/assessment-report/temozolomide-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Temozolomide Teva

Adopted

Reference Number: EMEA/CHMP/567027/2009

English (EN) (32.7 KB - PDF)

**First published:** 19/11/2009

**Last updated:** 19/11/2009

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-teva_en.pdf)

#### More information on Temozolomide Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/05/2024

## Share this page

[Back to top](#main-content)